Merck’s Keytruda Fails in Late-Stage HCC Trial

Merck’s vaunted PD-1 inhibitor Keytruda took a stumble in a late-stage trial as a treatment of patients with advanced hepatocellular carcinoma (HCC) who were previously treated with systemic therapy. In the pivotal Phase III KEYNOTE-240 trial, Keytruda plus best supportive care failed to hit endpoints in both overall survival and progression-free survival in comparison to placebo and best supportive care.
Read more...

;